(Q37622900)

21 August 2017

1 reference

title

Antituberculous vaccine development: a perspective for the endemic world (English)

1 reference

21 August 2017

Indu Verma

1

1 reference

21 August 2017

Ajay Grover

series ordinal

2

1 reference

21 August 2017

publication date

1 November 2009

1 reference

Expert Review of Vaccines

21 August 2017

published in

1 reference

21 August 2017

volume

8

1 reference

21 August 2017

issue

11

1 reference

21 August 2017

page(s)

1547-1553

1 reference

The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG?

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

The success and failure of BCG - implications for a novel tuberculosis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

Cross-reactive immune responses against Mycobacterium bovis BCG in mice infected with non-tuberculous mycobacteria belonging to the MAIS-Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

Recent progress in the development and testing of vaccines against human tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

Host-pathogen interactions in latent Mycobacterium tuberculosis infection: identification of new targets for tuberculosis intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

The tuberculosis vaccine challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

Differential effects of prior exposure to environmental mycobacteria on vaccination with Mycobacterium bovis BCG or a recombinant BCG strain expressing RD1 antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

An essential role for phoP in Mycobacterium tuberculosis virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

Therapy of tuberculosis in mice by DNA vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

Pulmonary necrosis resulting from DNA vaccination against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

Post-exposure vaccination against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

Adjunct immunotherapy with Ag85 complex proteins based subunit vaccine in a murine model of Mycobacterium tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

Peripheral blood and pleural fluid mononuclear cell responses to low-molecular-mass secretory polypeptides of Mycobacterium tuberculosis in human models of immunity to tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

Has BCG attenuated to impotence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.111

21 January 2018

Identifiers

DOI

10.1586/ERV.09.111

1 reference

21 August 2017

1 reference